The FDA has granted accelerated approval of Avastin (bevacizumab, from Genentech) for patients with glioblastoma with progressive disease following prior therapy.
Drugs in the Pipeline
Genentech announced that its Phase 3 study of Avastin (bevacizumab) plus chemotherapy following surgery in patients with early-stage colon cancer did not meet its primary endpoint of improvement in disease-free survival.
Genentech is warning healthcare providers of 36 reports of intraocular adverse events following the off-label intravitreal use of Avastin (bevacizumab) injection.
Genentech has received reports of several cases of microangiopathic hemolytic anemia (MAHA) in patients with solid tumors receiving Avastin (bevacizumab) in combination with Sutent (sunitinib malate, from Pfizer).
The FDA has granted Genentech accelerated approval for Avastin (bevacizumab), in combination with paclitaxel, for the treatment of metastatic HER2-negative breast cancer in chemotherapy-naïve patients.